Neural engineering startup Science Corporation has secured $230 million in a Series C funding round to accelerate the commercialization of its PRIMA retinal implant. This significant capital injection, backed by heavyweight investors including Khosla Ventures and IQT (the investment arm of the U.S. intelligence community), brings the company's total funding to approximately $490 million. Founded in 2021 by Max Hodak, the company is positioning itself as a leader in the burgeoning field of brain-computer interfaces and neural prosthetics.

The core technology addresses geographic atrophy, an advanced stage of macular degeneration that leads to permanent loss of central vision. The PRIMA system works through a sophisticated hardware pairing: specialized glasses project near-infrared light patterns onto a wireless chip implanted beneath the retina. This chip then converts the light into electrical signals, bypassing damaged photoreceptors to stimulate the optic nerve directly and restore visual perception.

Results from clinical trials have been encouraging, showing marked improvements in visual acuity over a 12-month period. While Science Corp prepares for a commercial rollout in Europe later this year, it remains in close coordination with the Food and Drug Administration for U.S. regulatory clearance. The success of this funding round underscores growing investor confidence in high-stakes neurotechnology and its potential to solve long-standing medical challenges.

Neural engineering startup Science Corporation has secured $230 million in a Series C funding round to accelerate the commercialization of its PRIMA retinal implant. This significant capital injection, backed by heavyweight investors including Khosla Ventures and IQT (the investment arm of the U.S. intelligence community), brings the company's total funding to approximately $490 million. Founded in 2021 by Max Hodak, the company is positioning itself as a leader in the burgeoning field of brain-computer interfaces and neural prosthetics.

The core technology addresses geographic atrophy, an advanced stage of macular degeneration that leads to permanent loss of central vision. The PRIMA system works through a sophisticated hardware pairing: specialized glasses project near-infrared light patterns onto a wireless chip implanted beneath the retina. This chip then converts the light into electrical signals, bypassing damaged photoreceptors to stimulate the optic nerve directly and restore visual perception.

Results from clinical trials have been encouraging, showing marked improvements in visual acuity over a 12-month period. While Science Corp prepares for a commercial rollout in Europe later this year, it remains in close coordination with the Food and Drug Administration for U.S. regulatory clearance. The success of this funding round underscores growing investor confidence in high-stakes neurotechnology and its potential to solve long-standing medical challenges.